This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Effect of Vitamin D Treatment in Primary Hyperparathyroidism

This study has been completed.
Information provided by (Responsible Party):
University of Aarhus Identifier:
First received: May 5, 2008
Last updated: October 23, 2013
Last verified: August 2013
The primary aim of the study is to assess whether 6-months of vitamin D supplements can decrease PTH compared with placebo treatment in primary hyperparathyroidism.

Condition Intervention Phase
Vitamin D Deficiency Primary Hyperparathyroidism Hypercalcemia Drug: Cholecalciferol Phase 2 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Effect of Vitamin D Treatment in Primary Hyperparathyroidism

Resource links provided by NLM:

Further study details as provided by University of Aarhus:

Primary Outcome Measures:
  • Decrease in Preoperative P-PTH [ Time Frame: 25 weeks ]
    Decrease in plasma PTH after 25 weeks of preoperative vitamin D treatment compared with the plasebo Group.

Secondary Outcome Measures:
  • Improved Muscular Function [ Time Frame: One Year ]
  • Reduced Postoperative Hypocalcemia [ Time Frame: Postoperative week ]
  • Increase in Quality of Life [ Time Frame: One year ]
  • Increased Bone Mineral Density [ Time Frame: One year ]
  • Increase in Trabecular and Cortical vBMD Measured by QCT and pQCT of Hip, Spine and Forearm [ Time Frame: one year ]

Enrollment: 46
Study Start Date: May 2008
Study Completion Date: August 2013
Primary Completion Date: August 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Vitamin D group
Cholecalciferol 1400 IU, 2 tablets once daily in 52 weeks
Drug: Cholecalciferol
2800 IE daily in 52 weeks
Other Name: vitamin D
Placebo Comparator: Placebo group
Placebo, two tablets daily in 52 weeks.
Drug: Cholecalciferol
2800 IE daily in 52 weeks
Other Name: vitamin D

Detailed Description:
The study investigates effects and safety of six months of vitamin D supplementation before and after surgery in primary hyperparathyroidism. Effects are assessed as changes in calcium homeostasis, bone metabolism, quality of life, and muscle strength and function.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • P-Ca-ion > 1,30 mmol/l
  • P-PTH > 5 pmol/l
  • P-OH25-vitamin D < 80 nmol/l

Exclusion Criteria:

  • P-creatinin > 120 mumol/l
  • usage of Etalpha, Mimpara
  • Cancer
  • Sarcoidosis
  • malabsorption
  • pancreatitis
  • alcohol abuse
  • pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00674154

Osteoporoseklinikken, Aarhus University Hospital, THG
Aarhus C, Denmark, 8000
Sponsors and Collaborators
University of Aarhus
Principal Investigator: Lars Rolighed, MD
Study Director: Lars Rejnmark, MD,PhD,DrMed
  More Information

Responsible Party: University of Aarhus Identifier: NCT00674154     History of Changes
Other Study ID Numbers: PHPT-20080011
Study First Received: May 5, 2008
Results First Received: August 6, 2013
Last Updated: October 23, 2013

Keywords provided by University of Aarhus:
Vitamin D
Primary hyperparathyroidism

Additional relevant MeSH terms:
Vitamin D Deficiency
Hyperparathyroidism, Primary
Parathyroid Diseases
Endocrine System Diseases
Deficiency Diseases
Nutrition Disorders
Calcium Metabolism Disorders
Metabolic Diseases
Water-Electrolyte Imbalance
Vitamin D
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents processed this record on September 19, 2017